Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Cboe UK • CHF Novartis AG (NOVNZ.XC) Follow Compare 95.45 -6.13 (-6.03%) At close: March 11 at 4:19:58 PM GMT Comparisons Indicators Technicals Corporate Events Line Candle Baseline Mountain Bar Step Baseline Delta HLC Wave Scatterplot Histogram Range Channel Colored Line Colored Mountain Colored Step Colored Bar Colored HLC Volume Candle Hollow Candle Step Mountain Vertex Line Vertex Step Vertex Mountain Vertex Baseline Delta Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for NOVNZ.XC 1D 5D -4.17% 1M -1.66% 3M 7.56% 6M -3.52% YTD 7.72% 1Y 8.43% 5Y 19.06% All 19.06% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours 1 day 1 week 1 month 3 months Recent News: NOVNZ.XC View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Molecular Partners AG (MLLCF) (FY 2024) Earnings Call Highlights: Strategic Shifts and ... Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting 3 Top Cancer Biotechs to Keep An Eye On in 2025 ITM targets US approval for radiopharmaceutical after Phase III readout Novartis AG (NVS): Among the Best Undervalued Stocks to Invest In Now Novartis Near Buy Point; Earns Near-Best Overall Rating Novartis Earnings Surprised The Street; Still Going Strong Novartis Gets CHMP Opinion for Label Expansion of Fabhalta 3 Dividend Stocks That Are No-Brainer Buys Right Now Q4 2024 PTC Therapeutics Inc Earnings Call Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)